Overview

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

Status:
Completed

Trial end date:
2018-07-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma [mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) ]compared to that achieved with therapy in the control arm.

Phase:

Phase 3

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Collaborators:

Seagen Inc.
Seattle Genetics, Inc.

Treatments:

Antibodies, Monoclonal
Bexarotene
Brentuximab Vedotin
Methotrexate